End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.52 EUR | +0.16% |
|
+2.77% | -10.20% |
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.20% | 17.19B | - | ||
-3.18% | 181B | C+ | ||
-2.68% | 105B | C | ||
-2.23% | 67.55B | A | ||
-6.46% | 46.39B | B- | ||
+6.78% | 40.93B | B+ | ||
+20.09% | 31.63B | B | ||
+12.12% | 24.28B | A- | ||
-6.67% | 23.46B | A- | ||
-12.70% | 21.95B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAX Stock
- BAX Stock
- Ratings Baxter International Inc.